151 related articles for article (PubMed ID: 22840462)
1. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer.
Krüger K; Stefansson IM; Collett K; Arnes JB; Aas T; Akslen LA
Breast; 2013 Jun; 22(3):282-8. PubMed ID: 22840462
[TBL] [Abstract][Full Text] [Related]
2. Quantifying tumour vascularity in non-luminal breast cancers.
Kraby MR; Opdahl S; Akslen LA; Bofin AM
J Clin Pathol; 2017 Sep; 70(9):766-774. PubMed ID: 28249942
[TBL] [Abstract][Full Text] [Related]
3. Vascular proliferation is a prognostic factor in breast cancer.
Arnes JB; Stefansson IM; Straume O; Baak JP; Lønning PE; Foulkes WD; Akslen LA
Breast Cancer Res Treat; 2012 Jun; 133(2):501-10. PubMed ID: 21947750
[TBL] [Abstract][Full Text] [Related]
4. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
5. Vascular proliferation is increased in basal-like breast cancer.
Nalwoga H; Arnes JB; Stefansson IM; Wabinga H; Foulkes WD; Akslen LA
Breast Cancer Res Treat; 2011 Dec; 130(3):1063-71. PubMed ID: 21874512
[TBL] [Abstract][Full Text] [Related]
6. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
7. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma.
Vartanian RK; Weidner N
Am J Pathol; 1994 Jun; 144(6):1188-94. PubMed ID: 7515558
[TBL] [Abstract][Full Text] [Related]
8. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
11. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.
Bujor IS; Cioca A; Ceaușu RA; Veaceslav F; Nica C; Cîmpean AM; Raica M
In Vivo; 2018; 32(1):79-83. PubMed ID: 29275302
[TBL] [Abstract][Full Text] [Related]
14. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
15. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
[TBL] [Abstract][Full Text] [Related]
16. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.
Papantoniou VJ; Souvatzoglou MA; Valotassiou VJ; Louvrou AN; Ambela C; Koutsikos J; Lazaris D; Christodoulidou JK; Sotiropoulou MG; Melissinou MJ; Perperoglou A; Tsiouris S; Zerva CJ
Breast Cancer Res; 2004; 6(2):R56-62. PubMed ID: 14979918
[TBL] [Abstract][Full Text] [Related]
17. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?
Jacobs TW; Siziopikou KP; Prioleau JE; Raza S; Baum JK; Hayes DF; Schnitt SJ
Mod Pathol; 1998 Mar; 11(3):259-64. PubMed ID: 9521472
[TBL] [Abstract][Full Text] [Related]
18. Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes.
Dikicioglu E; Barutca S; Meydan N; Meteoglu I
Int J Clin Pract; 2005 Sep; 59(9):1039-44. PubMed ID: 16115179
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
